Compare RKLB & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RKLB | TEVA |
|---|---|---|
| Founded | 2006 | 1901 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.6B | 30.2B |
| IPO Year | N/A | N/A |
| Metric | RKLB | TEVA |
|---|---|---|
| Price | $53.68 | $30.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 9 |
| Target Price | ★ $50.38 | $30.56 |
| AVG Volume (30 Days) | ★ 20.3M | 10.5M |
| Earning Date | 11-10-2025 | 01-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.62 |
| Revenue | $554,535,000.00 | ★ $16,776,000,000.00 |
| Revenue This Year | $40.19 | $4.74 |
| Revenue Next Year | $48.56 | $0.48 |
| P/E Ratio | ★ N/A | $48.77 |
| Revenue Growth | ★ 52.42 | 0.02 |
| 52 Week Low | $14.71 | $12.47 |
| 52 Week High | $73.97 | $30.44 |
| Indicator | RKLB | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 53.33 | 80.15 |
| Support Level | $52.68 | $28.00 |
| Resistance Level | $65.18 | $30.44 |
| Average True Range (ATR) | 4.14 | 0.65 |
| MACD | 1.36 | 0.07 |
| Stochastic Oscillator | 54.90 | 91.36 |
Rocket Lab Corp is engaged in space, building rockets, and spacecraft. It provides end-to-end mission services that provide frequent and reliable access to space for civil, defense, and commercial markets. It designs and manufactures the Electron and Neutron launch vehicles and Photon satellite platform. Rocket Lab's Electron launch vehicle has delivered multiple satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. The business operates in two segments Launch Services and Space Systems. Geographically it serves Japan, Germany, and rest of the world and earns key revenue from the United States.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.